Dr. Usmani on Impact of BCMA on the Myeloma Treatment Landscape

Saad Z. Usmani, MD, FACP



Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses how the target BCMA is impacting the multiple myeloma treatment landscape.

<<< 17th International Myeloma Workshop
Printer Printing...